IGF2 and Alzheimer disease: In light of evidence linking the drug galantamine to an increase in hippocampal IGF-II mRNA levels in a mouse model [22], we also excluded patients with AD who had already started treatment with any type of acetylcholinesterase inhibitor at the time of collection of CSF (10 individuals).